Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo-Reference-Cited by-同舟云学术

Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo

Published:2013-08-21 Issue:1 Volume:3 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Cufí Sílvia,Bonavia Rosa,Vazquez-Martin Alejandro,Oliveras-Ferraros Cristina,Corominas-Faja Bruna,Cuyàs Elisabet,Martin-Castillo Begoña,Barrajón-Catalán Enrique,Visa Joana,Segura-Carretero Antonio,Joven Jorge,Bosch-Barrera Joaquim,Micol Vicente,Menendez Javier A.

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/srep02459.pdf

Reference74 articles.

1. Rosell, R. et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 361, 958–67 (2009).

2. Rosell, R. et al. Predictive biomarkers in the management of EGFR mutant lung cancer. Ann N Y Acad Sci 1210, 45–52 (2010).

3. Rosell, R. et al. Non-small-cell lung cancer harbouring mutations in the EGFR kinase domain. Clin Transl Oncol 12, 75–80 (2010).

4. Rosell, R. et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13, 239–46 (2012).

5. Santarpia, M., De Pas, T. M., Altavilla, G., Spaggiari, L. & Rosell, R. Moving towards molecular-guided treatments: erlotinib and clinical outcomes in non-small-cell lung cancer patients. Future Oncol 9, 327–45 (2013).

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular Evidence of the Bio-activities of Traditional Home Medicine Ingredients;Current Topics in Medicinal Chemistry;2024-07-02

2. Silibinin is a suppressor of the metastasis-promoting transcription factor ID3;Phytomedicine;2024-06

3. The long non-coding RNA CCAT1 promotes erlotinib resistance in cholangiocarcinoma by inducing epithelial-mesenchymal transition via the miR-181a-5p/ROCK2 axis;American Journal of Cancer Research;2024

4. Silybum marianum: An Overview of its Phytochemistry and Pharmacological Activities with Emphasis on Potential Anticancer Properties;Anti-Cancer Agents in Medicinal Chemistry;2023-08

5. Naturally Occurring Compounds as Potential Inhibitors of Epidermal Growth Factor Receptors (EGFRs);Combinatorial Chemistry & High Throughput Screening;2023-05